Quality of life in Swedish children with eczema
Quality of life in Swedish children with eczema
复制标题
DOI：
10.2340/00015555-0245
复制
发表时间：
2007-01-01
影响因子：
3.6
通讯作者：
Wahlgren, Carl-Fredrik
中科院分区：
文献类型：
--
作者：
Ganemo, Agneta;Svensson, Ake;Wahlgren, Carl-Fredrik
儿童湿疹的负担很多，有些可以通过生活质量（QoL）问卷进行评估。78名瑞典儿童患有轻度至重度湿疹（“特应性皮炎”，Besnier），符合既定的诊断标准，研究湿疹对生活质量的影响。这是用经过验证的问卷测量的：婴儿皮肤病生活质量指数（IDQOL），儿童皮肤病生活质量指数（CDLQI）和皮肤病家庭影响问卷（DFI）。该研究还包括湿疹严重程度评分。IDQOL的中位评分为7.0（范围1-18），CDLQI为6.0（范围2-18），DFI为8.0（范围0-27）。男生和女生的成绩没有显著差异。年龄较小的儿童的DFI评分高于年龄较大的儿童，患有湿疹和哮喘、食物过敏/不耐受、过敏性鼻结膜炎或荨麻疹的儿童的DFI评分也较高。生活质量评分与拉伊卡& Langeland评分显著相关，但与客观SCORAD无相关性。在这项研究中的生活质量工具的结果清楚地表明，儿童湿疹影响儿童和他们的家庭的生活质量。生活质量数据提供了一个面向病人的结果衡量的重要性，了解病人和他们的家庭的情况。这些信息也可以用于干预研究和湿疹护理的医疗资源分配。
The burdens of childhood eczema are many and some can be assessed with quality of life (QoL) questionnaires. Seventy-eight Swedish children with mild-to-severe eczema ("atopic dermatitis", prurigo Besnier), fulfilling established diagnostic criteria, were investigated for the effect of eczema on QoL. This was measured with validated questionnaires: the Infants' Dermatitis Quality of Life Index (IDQOL), the Children's Dermatology Life Quality Index (CDLQI), and the Dermatitis Family Impact Questionnaire (DFI). The study also included scoring of eczema severity. The median score was 7.0 (range 1-18) for IDQOL, 6.0 (range 2-18) for the CDLQI, and 8.0 (range 0-27) for DFI. There was no significant difference in scores between boys and girls. The DFI scores were higher for younger than for older children, and also higher for those with both eczema and asthma, food allergy/intolerance, allergic rhinoconjunctivitis or urticaria. The QoL scores correlated significantly with the Rajka & Langeland score, but not with objective SCORAD. The outcome of the QoL instruments in this study clearly demonstrates that childhood eczema affects the children's and their families' QoL. QoL data offers a patient-oriented outcome measure of importance for understanding the patients' and their families' situation. Such information can also be used in intervention studies and in the allocation of healthcare resources to eczema care.